The Division of Clinical Translational Neuroscience is focused on 1) Discovery Research to uncover disease mechanisms, novel biomarkers, and candidate treatments of CNS disorders; and 2) Clinical Research for translating high impact discoveries from the laboratory to the bedside.
Over the past 30 years, this Division has been involved with the development of many of the most successful diagnostic and therapeutic products used in neuropsychiatry today. For example, the Division was involved with the Phase 1, Phase 2, and Phase 3 studies of AmyvidTM, the first FDA approved PET scan molecular imaging diagnostic aid for detecting brain amyloid plaques in Alzheimer’s disease.
Upper images show an Alzheimer’s patient, compared to normal control in lower images.
Neuropsychiatric Imaging Research Lab